About the 2019 Country 2 Country 4 Cancer Ride

After the great success of the last three editions of the European Country 2 Country 4 Cancer ride,  Bristol-Myers Squibb   employees from across Europe will again ride over 3’600 km from Germany to the UK. Along the way, they will ride through Switzerland, Italy, France and Spain, all to raise funds for cancer research and organisations that support cancer patients in Europe. Each of the organisations benefiting are members of the Union for International Cancer Control.

In this 4th edition of the ride starting on 9 September 2019 and lasting 18 days, over 80 European  Bristol-Myers Squibb   team members will be riding in 6 different country teams and each group will be performing a leg of the ride averaging 720 km in 3 days.

Raising funds for SMILfonden  

Cancer is among the leading causes of death worldwide. Each year, there are 18.1  million new cases and 9.6 million    cancer-related deaths worldwide, and these numbers are growing.

This is why the Team Nordics – riding 720km across France and Spain – has chosen to support  SMILfonden  in its mission to support cancer patients.

Encourage your colleagues, families and friends to donate, as cancer affects us all.

Who are the riders

The participants are novice riders, who have committed themselves to 5 months of intensive training to complete their portion of the ride. Some are cancer survivors, others have witnessed the devastating impact of cancer on friends and family. Their kilometers will help raise funds to fight against cancer by supporting SMILfonden, a member of the Union for International Cancer Control.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About the Union for International Cancer Control

The  Union for International Cancer Control  (UICC) is dedicated to taking the lead in convening, capacity building and advocacy initiatives that unite the cancer community to reduce the global cancer burden, promote greater equity, and integrate cancer control into the world health and development agenda.